ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation

Mose Hayes, Cynthia Lan, Jingsheng Yan, Yang Xie, Toby Gray, Robin H. Amirkhan, Jonathan E. Dowell

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background: Overexpression of excision repair cross complementing group 1 (ERCC1), a DNA repair enzyme, is associated with resistance to cisplatin. Materials and Methods: Tissues from 73 patients with squamous cell carcinoma of the head and neck (HNSCC) who received concurrent cisplatin and radiation was analyzed immunohistochemically to determine if ERCCI expression predicted for survival and response. Expression was scored as follows: 0=0% tumor nuclei positive, 1+=<50%, 2+=50-75% and 3+=>75%. Results: ERCC1 expression was 0 in 0%, 1+ (14%), 2+ (42%) and 3+ (44%). In uni- and multivariate analyses, 3+ ERCC1 expression was not a significant predictor of survival or response. Median survival for the ERCC1 3+ patients was 2.9 years versus 2.1 years for the ERCC1 <3+ group (p=0.44). Conclusion: In this retrospective review of HNSCC patients receiving concurrent cisplatin and radiation, ERCC1 expression was not a significant predictor of survival or response.

Original languageEnglish (US)
Pages (from-to)4135-4140
Number of pages6
JournalAnticancer Research
Volume31
Issue number12
StatePublished - Dec 1 2011

Keywords

  • Cisplatin
  • DNA repair
  • ERCC1 protein
  • Head and neck neoplasms
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation'. Together they form a unique fingerprint.

Cite this